#USA #San Francisco #Healthcare Conference #Halia Therapeutics #Obesity Treatment

Halia Therapeutics to Showcase Innovations at Major Healthcare Events

Halia Therapeutics is making headlines as the biopharmaceutical company prepares to showcase its research at two pivotal health forums taking place in San Francisco: the 43rd J.P. Morgan Healthcare Conference (January 13 – 16, 2025) and the 1st Annual BioPharma Obesity Innovation Forum (January 11, 2025). The company’s leadership team, headed by Dr. David J. Bearss, will not only attend these conferences but also actively participate in discussions aimed at revolutionizing treatments for chronic inflammation and related disorders.

Conference Highlights

At the BioPharma Obesity Innovation Forum, Dr. Bearss will present on a groundbreaking treatment, HT-6184, which stands to be a game-changer in managing the chronic inflammatory effects of obesity. This presentation is particularly significant as HT-6184 aims at inhibiting the protein NEK7, directly affecting NLRP3 inflammasome activity to resolve inflammation associated with various conditions linked to obesity.

Presentation Details

• - Title: Targeting Inflammation in Obesity: HT-6184 as a Synergistic Partner to GLP-1 Agonists for Enhanced Glucose Control and Weight Loss
• - Date: January 11, 2025
• - Time: 11:40 AM PST
• - Presenter: Dr. David J. Bearss, President and CEO of Halia Therapeutics
• - Location: Marines' Memorial Club, San Francisco

Dr. Bearss will delve into the mechanisms by which HT-6184 can significantly improve glucose control and facilitate weight loss, thereby impacting patient outcomes positively.

Participation in the J.P. Morgan Healthcare Conference

Furthermore, during the J.P. Morgan Healthcare Conference, Dr. Bearss will contribute as a panelist at the WuXi Global Forum 2025. This will provide an excellent platform for further discussions surrounding innovations in biopharmaceutical research and investment opportunities.

Roundtable Discussion Details

• - Date: January 14, 2025
• - Time: 5:00 PM – 6:00 PM PST
• - Presenter: Dr. David J. Bearss
• - Location: Continental Ballroom 5, Hilton San Francisco Union Square

In addition to the presentations, Dr. Bearss and his team will be available for one-on-one meetings with potential investors and strategic partners. Interested parties are encouraged to schedule these meetings through Logan Berrett at log[email protected].

About Halia Therapeutics

Founded and headquartered in Lehi, Utah, Halia Therapeutics is at the forefront of developing novel therapies aimed at alleviating chronic inflammatory disorders and neurodegenerative diseases. Among their leading programs is HT-6184, which has successfully completed a Phase I clinical trial establishing its safety and tolerability. Furthermore, Halia has launched two Phase II trials focusing on its effectiveness for low-risk myelodysplastic syndromes and its impact on inflammation and pain.

With a commitment to improving patient lives through innovation, Halia Therapeutics is undeniably a company to watch in 2025.

For more information about Halia Therapeutics and its latest updates, visit www.haliatx.com and follow them on LinkedIn and Twitter (X).